Hero

Celyad to Present Data at 24th Congress of the European Hematology Association

1

Celyad to Present Data at 24th Congress of the European Hematology Association

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

2

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces May 2019 Investor Conference Schedule

3

Celyad Announces May 2019 Investor Conference Schedule

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad to Present Data at 24th Congress of the European Hematology Association

Celyad to Present Data at 24th Congress of the European Hematology Association

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces First Quarter 2019 Financial Results and Recent Business Highlights

Celyad Announces May 2019 Investor Conference Schedule

Celyad Announces May 2019 Investor Conference Schedule

Discover all news

Carousel

Social Feed

Frédéric Lehmann, VP Clinical Development & Medical Affairs de @CelyadSA , a donné une présentation sur les CAR-T c… https://t.co/UJiij5wT9v

2 days ago

Frédéric Lehmann, VP Clinical Development & Medical Affairs de @CelyadSA , a donné une présentation sur les CAR-T c… https://t.co/UJiij5wT9v

Celyad to Present Data at 24th Congress of the European Hematology Association #EHA2019 $CYAD… https://t.co/li35pGo454

2 days ago

Celyad to Present Data at 24th Congress of the European Hematology Association #EHA2019 $CYAD… https://t.co/li35pGo454

Ce midi, @ChristianHomsy et Anne Moore, VP Corporate Strategy ont présenté le potentiel de la technologie CAR-T dév… https://t.co/k8IunPKUy6

6 days ago

Ce midi, @ChristianHomsy et Anne Moore, VP Corporate Strategy ont présenté le potentiel de la technologie CAR-T dév… https://t.co/k8IunPKUy6

Recently, @CelyadSA’s leadership team spoke with @ScripJo from @PharmaScrip to discuss the importance of the coming… https://t.co/WPlwHHFXHh

6 days ago

Recently, @CelyadSA’s leadership team spoke with @ScripJo from @PharmaScrip to discuss the importance of the coming… https://t.co/WPlwHHFXHh

Frédéric Lehmann, VP Clinical Development & Medical Affairs de @CelyadSA , a donné une présentation sur les CAR-T c… https://t.co/UJiij5wT9v

2 days ago

Frédéric Lehmann, VP Clinical Development & Medical Affairs de @CelyadSA , a donné une présentation sur les CAR-T c… https://t.co/UJiij5wT9v

Celyad to Present Data at 24th Congress of the European Hematology Association #EHA2019 $CYAD… https://t.co/li35pGo454

2 days ago

Celyad to Present Data at 24th Congress of the European Hematology Association #EHA2019 $CYAD… https://t.co/li35pGo454

Ce midi, @ChristianHomsy et Anne Moore, VP Corporate Strategy ont présenté le potentiel de la technologie CAR-T dév… https://t.co/k8IunPKUy6

6 days ago

Ce midi, @ChristianHomsy et Anne Moore, VP Corporate Strategy ont présenté le potentiel de la technologie CAR-T dév… https://t.co/k8IunPKUy6

Recently, @CelyadSA’s leadership team spoke with @ScripJo from @PharmaScrip to discuss the importance of the coming… https://t.co/WPlwHHFXHh

6 days ago

Recently, @CelyadSA’s leadership team spoke with @ScripJo from @PharmaScrip to discuss the importance of the coming… https://t.co/WPlwHHFXHh